- Home
- ANPA vs AVTX Comparison
ANPA vs AVTX Comparison
Compare ANPA & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANPA
- AVTX
- Stock Information
- Founded
- ANPA 2016
- AVTX 2011
- Country
- ANPA Hong Kong
- AVTX United States
- Employees
- ANPA N/A
- AVTX N/A
- Industry
- ANPA
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ANPA
- AVTX Health Care
- Exchange
- ANPA Nasdaq
- AVTX Nasdaq
- Market Cap
- ANPA 300.0M
- AVTX 248.3M
- IPO Year
- ANPA 2025
- AVTX 2015
- Fundamental
- Price
- ANPA $32.69
- AVTX $17.59
- Analyst Decision
- ANPA
- AVTX Strong Buy
- Analyst Count
- ANPA 0
- AVTX 9
- Target Price
- ANPA N/A
- AVTX $30.14
- AVG Volume (30 Days)
- ANPA 7.0K
- AVTX 387.2K
- Earning Date
- ANPA 09-30-2025
- AVTX 11-06-2025
- Dividend Yield
- ANPA N/A
- AVTX N/A
- EPS Growth
- ANPA N/A
- AVTX N/A
- EPS
- ANPA 0.06
- AVTX N/A
- Revenue
- ANPA $5,832,684.00
- AVTX $192,000.00
- Revenue This Year
- ANPA N/A
- AVTX N/A
- Revenue Next Year
- ANPA N/A
- AVTX N/A
- P/E Ratio
- ANPA $545.11
- AVTX N/A
- Revenue Growth
- ANPA N/A
- AVTX N/A
- 52 Week Low
- ANPA $2.80
- AVTX $3.39
- 52 Week High
- ANPA $54.75
- AVTX $19.41
- Technical
- Relative Strength Index (RSI)
- ANPA N/A
- AVTX 60.19
- Support Level
- ANPA N/A
- AVTX $14.01
- Resistance Level
- ANPA N/A
- AVTX $18.52
- Average True Range (ATR)
- ANPA 0.00
- AVTX 1.47
- MACD
- ANPA 0.00
- AVTX -0.02
- Stochastic Oscillator
- ANPA 0.00
- AVTX 75.86
About ANPA Rich Sparkle Holdings Limited Ordinary Shares
Rich Sparkle Holdings Ltd is financial printing and corporate services provider which engaged in designing and printing financial print materials in Hong Kong. It service portfolio covers a myriad of deliverables, mainly including listing documents, financial reports, fund documents, circulars and announcements. The company's core business includes (i) financial printing services such as printing, typesetting and translation, (ii) advisory services including Environmental, Social and Governance Report and (iii) other services. Key revenue is generated from Financial printing services.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).